



Acquist Therapeutics, Inc.
Westfield, NJ 07090

Acquist Therapeutics to Provide Update on Lead Programs for Treating NASH and Gout

Company to Present at BIO Investor Forum in San Francisco

Westfield, NJ – September 25, 2018 – [Acquist Therapeutics, Inc.](#), a biopharmaceutical company committed to developing treatments that will better the lives of people with inflammatory diseases, today announced that the Company will update scientific findings and clinical development plans for its drug candidates in two diseases, nonalcoholic steatohepatitis (NASH) and gout. Acquist's Chief Executive, Dr. Raymond P. Warrell, Jr., will present at the BIO Investor Forum, held at the Westin St. Francis Hotel in San Francisco, on October 17, 2018 at 11:30AM.

In clinical trials involving more than 350 patients, Acquist investigators observed marked reductions in serum uric acid, a well-established central mediator of inflammation in a number of diseases. Acquist scientists have synthesized novel, patented derivatives with considerably greater safety and potency. These newer drug candidates are highly potent bifunctional inhibitors of two key enzymes that regulate both production and excretion of uric acid. Dr. Warrell's presentation will highlight recent results demonstrating markedly lower uric acid, as well as positive effects on both upstream and downstream biomarkers of NASH-related inflammation and liver fat formation.

The Company is currently seeking a Series A financing to complete robust randomized Phase 1a/b clinical trials for its lead candidate RLBN1127 in NASH and gout.

About NASH and Gout

Acquist targets diseases that share a common characteristic: excessive levels of serum uric acid, which can induce inflammation that leads to progressive illness, debilitation and organ failure. The Company is developing potentially transformational therapy for these illnesses that currently afflict at least 16 million patients in the U.S./EU and are considered epidemic in East Asia.

In NASH, high uric acid stimulates uptake of liver fat, triggering of inflammation, and progression to fibrosis/cirrhosis. All patients with gout have excess uric acid that leads to painful deforming arthritis, kidney failure, and possibly accelerated cardiovascular

disease. Fewer than 25% of gout patients actually respond to standard 1st-line treatment, and no drugs have yet been approved for NASH.

About Acquist

Acquist is focused on improving health for patients with inflammatory and metabolic diseases. Simultaneously targeting enzymes that regulate both production and excretion of uric acid, Acquist compounds are markedly more potent than standard monofunctional drugs and have demonstrated exceptional clinical activity. In NASH and gout, effective treatment could relieve both morbidity and mortality from these progressive illnesses. Further information can be accessed at www.acquistrx.com.

Contacts:

Brian M. Pinkston
Tiberend Strategic Advisors
bpinkston@tiberend.com
(212) 375-6298

SOURCE: Acquist Therapeutics, Inc.™